471 related articles for article (PubMed ID: 33385175)
1. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes.
Xing T; Yao WL; Zhao HY; Wang J; Zhang YY; Lv M; Xu LP; Zhang XH; Huang XJ; Kong Y
J Cell Physiol; 2024 Feb; 239(2):e31129. PubMed ID: 38192063
[TBL] [Abstract][Full Text] [Related]
3. Novel combinations to improve hematopoiesis in myelodysplastic syndrome.
Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC
Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H
Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
[TBL] [Abstract][Full Text] [Related]
5. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
6. Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes.
Cull AH; Rauh MJ
J Leukoc Biol; 2017 Aug; 102(2):209-219. PubMed ID: 28596252
[TBL] [Abstract][Full Text] [Related]
7. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
9. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
Steensma DP
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
[TBL] [Abstract][Full Text] [Related]
10. Targeting inflammation in lower-risk MDS.
Gonzalez-Lugo JD; Verma A
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):382-387. PubMed ID: 36485128
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
12. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM
Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762
[TBL] [Abstract][Full Text] [Related]
13. The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome.
Zheng L; Zhang L; Guo Y; Xu X; Liu Z; Yan Z; Fu R
Front Immunol; 2022; 13():1078421. PubMed ID: 36569863
[TBL] [Abstract][Full Text] [Related]
14. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution.
Ainciburu M; Ezponda T; Berastegui N; Alfonso-Pierola A; Vilas-Zornoza A; San Martin-Uriz P; Alignani D; Lamo-Espinosa J; San-Julian M; Jiménez-Solas T; Lopez F; Muntion S; Sanchez-Guijo F; Molero A; Montoro J; Serrano G; Diaz-Mazkiaran A; Lasaga M; Gomez-Cabrero D; Diez-Campelo M; Valcarcel D; Hernaez M; Romero JP; Prosper F
Elife; 2023 Jan; 12():. PubMed ID: 36629404
[TBL] [Abstract][Full Text] [Related]
15. The genetic and molecular pathogenesis of myelodysplastic syndromes.
Shallis RM; Ahmad R; Zeidan AM
Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
[TBL] [Abstract][Full Text] [Related]
16. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
[TBL] [Abstract][Full Text] [Related]
17. [Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes].
Nakajima H
Rinsho Ketsueki; 2023; 64(8):753-763. PubMed ID: 37673628
[TBL] [Abstract][Full Text] [Related]
18. Innate immune signaling in the myelodysplastic syndromes.
Starczynowski DT; Karsan A
Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
[TBL] [Abstract][Full Text] [Related]
19. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
20. [Research advance of hematopoietic microenvironment for myelodysplastic syndromes].
Fei CM; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1246-50. PubMed ID: 23114158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]